NASDAQ:ONVO - Nasdaq - US68620A2033 - Common Stock - Currency: USD
1.72
+0.06 (+3.61%)
The current stock price of ONVO is 1.72 USD. In the past month the price decreased by -53.19%. In the past year, price decreased by -86.97%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. The firm is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). The company is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
ORGANOVO HOLDINGS INC
Suite 100, 11555 Sorrento Valley Road
San Diego CALIFORNIA 92075 US
CEO: Keith Murphy
Employees: 20
Company Website: https://organovo.com/
Investor Relations: http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-irhome
Phone: 18582241000
The current stock price of ONVO is 1.72 USD. The price increased by 3.61% in the last trading session.
The exchange symbol of ORGANOVO HOLDINGS INC is ONVO and it is listed on the Nasdaq exchange.
ONVO stock is listed on the Nasdaq exchange.
ORGANOVO HOLDINGS INC (ONVO) has a market capitalization of 2.92M USD. This makes ONVO a Nano Cap stock.
ORGANOVO HOLDINGS INC (ONVO) currently has 20 employees.
The Revenue of ORGANOVO HOLDINGS INC (ONVO) is expected to grow by 126.67% in the next year. Check the estimates tab for more information on the ONVO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONVO does not pay a dividend.
ORGANOVO HOLDINGS INC (ONVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.49).
The outstanding short interest for ORGANOVO HOLDINGS INC (ONVO) is 8.04% of its float. Check the ownership tab for more information on the ONVO short interest.
ChartMill assigns a fundamental rating of 2 / 10 to ONVO. The financial health of ONVO is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ONVO reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS increased by 60.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -322.19% | ||
ROE | -3402.47% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 46% to ONVO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 96.31% and a revenue growth 126.67% for ONVO